Agenus
Open
$3.34
Prev. Close
$3.34
High
$3.35
Low
$3.29
Market Snapshot
$126.71M
2.0
-10.58
$103.46M
81
Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company is headquartered in Lexington, Massachusetts and currently employs 81 full-time employees. The company went IPO on 2000-02-04. The firm is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The firm has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.
Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. The company is headquartered in Lexington, Massachusetts and currently employs 81 full-time employees. The company went IPO on 2000-02-04. The firm is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The firm has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.
Recently from Cashu
Agenus Drives Immuno-Oncology Advancements Amid Biopharmaceutical Landscape Changes
Agenus Responds to Emerging Trends in the Biopharmaceutical Landscape Agenus continues to position itself at the forefront of immuno-oncology, driven by innovative therapies aimed at improving treatme…
Agenus Partners with Zydus Lifesciences to Enhance Biologics Manufacturing Capabilities
Agenus Partners with Zydus Lifesciences to Strengthen Biologics Manufacturing Capabilities Agenus Inc. solidifies its strategic positioning in the biopharmaceutical sector through a significant partne…
Agenus: Leading Innovation in Immuno-Oncology Amidst Market Dynamics
Agenus: Pioneering Immuno-Oncology Developments Amid Market Dynamics Agenus, a leading biotechnology company focused on immuno-oncology, continues to make significant strides in its research and devel…
Agenus Advances Immunotherapy with New Trials for AGEN1181 and Cancer Treatment Strategies
Agenus Advances Immunotherapy Pipeline with New Clinical Trial Initiatives Agenus, a biotechnology firm specializing in immunotherapy, announces significant developments in its clinical pipeline, part…